	US 12,213,984 B2
	Immunoregulatory agent
Yoshinori Fukui, Fukuoka (JP); Takehito Uruno, Fukuoka (JP); and Yuki Sugiura, Tokyo (JP)
Assigned to KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, Fukuoka (JP)
Filed by KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, Fukuoka (JP)
Filed on Nov. 8, 2021, as Appl. No. 17/521,335.
Application 17/521,335 is a division of application No. 15/775,895, granted, now 11,395,826, previously published as PCT/JP2016/084259, filed on Nov. 18, 2016.
Claims priority of application No. 2015-228190 (JP), filed on Nov. 20, 2015.
Prior Publication US 2022/0054506 A1, Feb. 24, 2022
Int. Cl. A61K 31/575 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 35/76 (2015.01); A61K 38/00 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61P 37/06 (2006.01); C07K 14/47 (2006.01)

CPC A61K 31/575 (2013.01) [A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 35/76 (2013.01); A61K 38/00 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61P 37/06 (2018.01); C07K 14/47 (2013.01)]

9 Claims

1. A method for regulating Rac-activating activity of DOCK2, the method comprising at least one of:

(i) forming an immune-privileged site by administering to a patient in need of treatment an effective amount of cholesterol 3-sulfate, a pharmacologically acceptable salt thereof, or a solvate thereof, to regulate DOCK2-mediated Rac activation;

(ii) forming an immune-privileged site by administering to a patient in need of treatment an effective amount of a SULT2B1b protein, or an expression vector of the SULT2B1b protein; and

(iii) destroying an immune-privileged site by administering to a patient in need of treatment an effective amount of an expression inhibition substance of the SULT2B1b protein,

wherein:

the SULT2B1b protein is a protein which comprises the amino acid sequence of SEQ ID NO: 2, or a protein which comprises an amino acid sequence formed by the deletion, substitution, or addition of 1 to 3 amino acids in the amino acid sequence of SEQ ID NO: 2, and acts to add a sulfonic acid group to the carbon at position 3 of cholesterol and generate cholesterol 3-sulfate, and

the expression inhibition substance of the SULT2B1b protein is siRNA or shRNA.